skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
ALK/TRK Inhibitor TSR-011 (Code C114287)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: ALK/TRK Inhibitor TSR-011

Definition: An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.

Label: ALK/TRK Inhibitor TSR-011

NCI Thesaurus Code: C114287 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL471796  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
ALK/TRK Inhibitor TSR-011
TSR-011

External Source Codes: 
PDQ Closed Trial Search ID 757983
PDQ Open Trial Search ID 757983 (check for NCI PDQ open clinical trial info)
NCI META CUI CL471796

Other Properties:
     Name Value (qualifiers indented underneath)
code C114287
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114287

Mainbox Bottom